Why Prime Medicine Stock Was Climbing Higher This Week
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.
Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies.
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
Got $100? Consider Buying These 2 Penny Stocks in October
You've likely heard that penny stocks are high-risk investments, and if so, you've heard right.
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Changes are afoot at the company, and investors welcomed them.
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
2 Growth Stocks That Could Make You Richer
Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the expanding commercial space industry with its small satellite launch services and vertical-integration strategy.
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
